Blocking adenosine signaling with A2A adenosine receptor antagonists or by genetic modification largely reinforces NK cell terminal maturation, tumor infiltration, effector functions as well as IFN-γ and TNF-α productions [189,190] (Figure 3). The gene discussed is IFNG; the disease is neoplasm.